RU93010275A - EYE DROPS "KERATONIK" - Google Patents

EYE DROPS "KERATONIK"

Info

Publication number
RU93010275A
RU93010275A RU93010275/14A RU93010275A RU93010275A RU 93010275 A RU93010275 A RU 93010275A RU 93010275/14 A RU93010275/14 A RU 93010275/14A RU 93010275 A RU93010275 A RU 93010275A RU 93010275 A RU93010275 A RU 93010275A
Authority
RU
Russia
Prior art keywords
eye drops
sodium
chloride
glutamic acid
riboflavin
Prior art date
Application number
RU93010275/14A
Other languages
Russian (ru)
Other versions
RU2056821C1 (en
Inventor
С.Н. Федоров
З.И. Мороз
С.А. Борзенок
Ю.А. Комах
Original Assignee
Межотраслевой научно-технический комплекс "Микрохирургия глаза"
Filing date
Publication date
Application filed by Межотраслевой научно-технический комплекс "Микрохирургия глаза" filed Critical Межотраслевой научно-технический комплекс "Микрохирургия глаза"
Priority to RU93010275A priority Critical patent/RU2056821C1/en
Priority claimed from RU93010275A external-priority patent/RU2056821C1/en
Publication of RU93010275A publication Critical patent/RU93010275A/en
Application granted granted Critical
Publication of RU2056821C1 publication Critical patent/RU2056821C1/en

Links

Claims (1)

Изобретение относится к медицине, а именно к офтальмологии, и может быть использовано для фармакологической защиты трансплантата после кератопластики и лечения эпителиально-эндотелиальной дистрофии. С целью разработки многокомпонентных глазных капель, улучшающих энергетический метаболизм в клетках заднего эпителия роговицы при любых процессах, нарушающих этот обмен, известные глазные капли, включающие натрия сукцинат, сорбитол, бензалкония хлорид и дистиллированную воду, дополнительно содержат натрия цитрат, натрия хлорид, глутаминовую кислоту, рибофлавина мононуклеотидфосфат при следующем соотношении компонентов, мас.%: натрия сукцинат шестиводный 0,3, натрия цитрат 5,5-водный 0,3, сорбилот 1,0, натрия хлорид 0,54, Л-глютаминовая кислота 0,2, рибофлавина мононуклеотидфосфат 0,01, бензалкония хлорид 0,01, вода дистиллированная для инъекций - остальное.The invention relates to medicine, namely to ophthalmology, and can be used for pharmacological protection of the graft after keratoplasty and treatment of epithelial-endothelial dystrophy. In order to develop multicomponent eye drops that improve energy metabolism in the corneal posterior epithelium cells in any processes that disturb this exchange, known eye drops, including sodium succinate, sorbitol, benzalkonium chloride and distilled water, additionally contain sodium citrate, sodium chloride, glutamic acid, Riboflavin mononucleotide phosphate in the following ratio of components, wt.%: sodium succinate six distilled 0.3, sodium citrate 5.5-water 0.3, sorbilot 1.0, sodium chloride 0.54, L-glutamic acid 0.2 mononukleotidfosfat riboflavin 0.01 0.01 benzalkonium chloride, distilled water for injection - the rest.
RU93010275A 1993-02-26 1993-02-26 Eye drops RU2056821C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU93010275A RU2056821C1 (en) 1993-02-26 1993-02-26 Eye drops

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU93010275A RU2056821C1 (en) 1993-02-26 1993-02-26 Eye drops

Publications (2)

Publication Number Publication Date
RU93010275A true RU93010275A (en) 1995-09-10
RU2056821C1 RU2056821C1 (en) 1996-03-27

Family

ID=20137834

Family Applications (1)

Application Number Title Priority Date Filing Date
RU93010275A RU2056821C1 (en) 1993-02-26 1993-02-26 Eye drops

Country Status (1)

Country Link
RU (1) RU2056821C1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006035969A1 (en) 2004-09-28 2006-04-06 Senju Pharmaceutical Co., Ltd. Ophthalmic composition containing xanthan gum and amino acid

Similar Documents

Publication Publication Date Title
US5106615A (en) Eyedrops having non-newtonian rheological properties
US5488069A (en) Ophthalmic pharmaceutical composition containing N-acetyl-cysteine and polyvinylalcohol
CA2355814A1 (en) Pharmaceutical composition for ophthalmic use
CA2339792A1 (en) Opthalmic solution with tetracycline for topical treatment of dry eye disease
Fisher et al. Allergic contact sensitivity to benzalkonium chloride: cutaneous, ophthalmic, and general medical implications
CA2154533A1 (en) Opthalmic preparation for use as artificial tear
CA2213339A1 (en) Method of treating adenosine depletion
ES2179193T3 (en) SYNERGIC COMBINATIONS OF ZIDOVUDINA, 1592U89 AND 3TC.
PT80079A (en) Process for the preparation of antiviral pharmaceutical preparations containing 2-diethylamino-2,2',6'-acetoxyxylidide (lidocaine)
US6395756B2 (en) Use of ophthalmic agent
KR970025612A (en) Pharmaceutical compositions, methods and apparatus for the prevention or treatment of dry eye or resulting diseases
BR0116251A (en) composition of artificial tears containing a combination of three demulcents
ES8707501A1 (en) Dihydropyridine-carboxylic acid amides, process for their preparation and their use in medicaments.
JPH03133936A (en) Gel-like protein shaping agent for ophthalmic application
US5270050A (en) Paracetamol-based pharmaceutical composition
MXPA03011613A (en) Ophthalmic composition containing n-acetylcysteine for the treat ment of dry-eye syndrome.
RU93010275A (en) EYE DROPS "KERATONIK"
BR9814053A (en) Lipophilic diesters of chelating agents
Reinert et al. Relationship of surrender and narcissism to involvement in alcohol recovery
Laibson et al. Double controlled comparison of IDU and trifluorothymidine in thirty-three patients with superficial herpetic keratitis.
ATE141506T1 (en) ANTINEOPLASTIC ACTIVE AND ENHANCEMENT OF THE ANTINEOPLASTIC EFFECT
CA2120001A1 (en) Flavopereirine-based pharmaceutical composition and use thereof for treating hiv
RU2056821C1 (en) Eye drops
Kläger et al. Topical immunoglobulins for epithelial herpes simplex keratitis
Oji Study of ketoconazole toxiciy in rabbit cornea and conjuctiva